In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 11.46 above Solid Biosciences Inc average.

Within Biotechnology & Pharmaceuticals industry 9 other companies have achieved higher Quick Ratio than Solid Biosciences Inc in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 209, from total ranking in the second quarter 2026 at 242.

Explain Quick Ratio?
How much Cash & cash equivalents SLDB�s has?
What are SLDB�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/SLDB/financial-strength

https://api.csimarket.com/api/v1/companies/SLDB/fundamentals

https://api.csimarket.com/api/v1/companies/SLDB/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

SLDB Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	-10.51 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	47.76 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	11.46	Subscribe	Subscribe	Subscribe	Subscribe
SLDB's Total Ranking	# 209	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	6.54 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-41.45 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 10
Healthcare Sector	# 53
Overall Market	# 209

Quick Ratio Statistics
High	Average	Low
26.88	10.73	1.68
(Mar 31 2021)		(Sep 30 2020)

Financial Statements
Solid Biosciences Inc 's Current Liabilities	$ 30 Millions	Visit SLDB's Balance sheet
Solid Biosciences Inc 's Cash & cash equivalent	$ 349 Millions	Visit SLDB's Balance sheet
Source of SLDB's Sales		Visit SLDB's Sales by Geography

Cumulative Solid Biosciences Inc 's Quick Ratio

SLDB's Quick Ratio for the trailling 12 Months

SLDB Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	3.92 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	57.64 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	12.77	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 3484	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	-2.93 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	8.05 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to SLDB Financial Strength Comparisons >> Go to Compare SLDB Quick Ratio to its Competitors

News about Solid Biosciences Inc Quick Ratio

Solid Biosciences Announces $109 Million Private Placement, Paving the Way for Revolutionary Genetic Medicines

Solid Biosciences Announces Groundbreaking $109 Million Private Placement for Advancing Precision Genetic Medicines
Charlestown, Mass., Jan. 08, 2024 - Solid Biosciences Inc. (Nasdaq: SLDB), a cutting-edge life sciences company dedicated to developing precision genetic medicines for neuromuscular and cardiac diseases, has made a groundbreaking announcement today. The company revealed that it has successfully entered into a securities purchase agreement with a select group of institutional accredited investors, paving the way for an approximately $108.9 million private placement.
This significant investment will serve as a major boost for Solid Biosciences, propelling their mission to revolutionize the treatment landscape for neuromuscular and cardiac diseases. The private placement is projected to be finalized on or about January 11, 2024, pending the completion of customary closing conditions. The meticulous execution of this partnership highlights Solid Biosciences commitment to adhering to applicable Nasdaq rules, and the pricing of the placement has specifically aimed to meet the Minimum Price requirement set by Nasdaq rules.

On the trailing twelve months basis SLDB Cash & cash equivalent soared by 47.76 % in Q3 2026 year on year, while Current Liabilities rose to $30 millions, this led to increase in in Solid Biosciences Inc 's Quick Ratio to 12.77, above SLDB average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 138 other companies have achieved higher Quick Ratio than Solid Biosciences Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 3446 to 3484.

Explain Quick Ratio?
How much Cash & cash equivalents SLDB�s has?
What are SLDB�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 139
Healthcare Sector	# 854
Within the Market	# 3484

trailing twelve months Quick Ratio Statistics
High	Average	Low
12.61	5.51	2.27
(Dec 31 2018)		(Mar 31 2018)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Artiva Biotherapeutics Inc	19.52	$ 320.347 Millions	$ 16.408 Millions
Palisade Bio Inc	19.50	$ 113.613 Millions	$ 5.826 Millions
Crispr Therapeutics Ag	16.12	$ 2,272.548 Millions	$ 140.962 Millions
Imagenebio Inc	15.68	$ 126.597 Millions	$ 8.075 Millions
Inhibikase Therapeutics Inc	14.92	$ 193.321 Millions	$ 12.957 Millions
Aura Biosciences Inc	13.93	$ 297.233 Millions	$ 21.337 Millions
Maze Therapeutics Inc	13.77	$ 389.658 Millions	$ 28.300 Millions
Vor Biopharma Inc	13.25	$ 481.551 Millions	$ 36.344 Millions
Tectonic Therapeutic Inc	13.05	$ 234.666 Millions	$ 17.986 Millions
Beam Therapeutics Inc	12.72	$ 1,043.873 Millions	$ 82.076 Millions
X4 Pharmaceuticals Inc	12.53	$ 187.701 Millions	$ 14.984 Millions
Odyssey Therapeutics, Inc.	12.49	$ 326.001 Millions	$ 26.101 Millions
Solid Biosciences Inc	11.46	$ 348.928 Millions	$ 30.454 Millions
Kalaris Therapeutics Inc	9.73	$ 82.856 Millions	$ 8.514 Millions
Zura Bio Limited	9.22	$ 187.652 Millions	$ 20.349 Millions
Protara Therapeutics Inc	8.83	$ 127.050 Millions	$ 14.391 Millions
Immunovant Inc	6.94	$ 722.274 Millions	$ 104.022 Millions
Repligen Corp	6.87	$ 862.979 Millions	$ 125.686 Millions
Compass Therapeutics Inc	6.69	$ 163.058 Millions	$ 24.368 Millions
Black Diamond Therapeutics Inc	6.62	$ 102.030 Millions	$ 15.405 Millions
Krystal Biotech Inc	6.45	$ 916.484 Millions	$ 142.144 Millions
Voyager Therapeutics Inc	6.35	$ 106.806 Millions	$ 16.813 Millions
Cabaletta Bio Inc	6.33	$ 299.383 Millions	$ 47.332 Millions
Cognition Therapeutics inc	6.00	$ 30.758 Millions	$ 5.128 Millions
Replimune Group Inc	5.57	$ 307.833 Millions	$ 55.271 Millions
Denali Therapeutics Inc	5.42	$ 516.196 Millions	$ 95.258 Millions
In8bio Inc	5.32	$ 13.973 Millions	$ 2.628 Millions
Scholar Rock Holding Corp	5.16	$ 413.599 Millions	$ 80.124 Millions
Revolution Medicines Inc	4.81	$ 3,651.385 Millions	$ 758.773 Millions
Caribou Biosciences Inc	4.71	$ 94.881 Millions	$ 20.144 Millions

Date modified: 2026-11-05T09:55:27+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.